CN109200046A - Application of the Cannabinoids compound in treatment neurodermatitis - Google Patents
Application of the Cannabinoids compound in treatment neurodermatitis Download PDFInfo
- Publication number
- CN109200046A CN109200046A CN201710538732.XA CN201710538732A CN109200046A CN 109200046 A CN109200046 A CN 109200046A CN 201710538732 A CN201710538732 A CN 201710538732A CN 109200046 A CN109200046 A CN 109200046A
- Authority
- CN
- China
- Prior art keywords
- tetrahydrocannabinol
- cbdv
- thcv
- cannabidivarin
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Abstract
The invention discloses Cannabinoids compounds or its pharmaceutical salt to prepare the purposes in the pharmaceutical composition for treating neurodermatitis, wherein the Cannabinoids compound can be selected from selected from one of tetrahydrocannabinol, cannabidiol, cannabidivarin, tetrahydrocannabinol or the Cannabinoids compound: (1) combination of tetrahydrocannabinol and tetrahydrocannabinol；(2) combination of cannabidiol and cannabidivarin；(3) combination of tetrahydrocannabinol and cannabidivarin；(4) combination of cannabidiol and tetrahydrocannabinol；(5) combination of cannabidiol, cannabidivarin and tetrahydrocannabinol；(6) combination of tetrahydrocannabinol, cannabidivarin and tetrahydrocannabinol.
Description
Technical field
The present invention relates to field of medicaments, in particular to the composition comprising one or more kinds of Cannabinoids compounds exists
Treat the application in neurodermatitis.
Background technique
Neurodermatitis is also known as lichen simplex chronicus, is a kind of limitation cutaneous nerve dysfunction dermatoses.It is
The chronic dermatosis of feature is turned to paroxysmal pruitus and skin moss.The cause of disease is still not clear, it is considered that with scratch for a long time
Grab, rub it is with psychoneural factor and certain external stimulus factors related, wherein mental element, which is presently considered to be, occurs this disease
Main inducing, mood swing, spiritual overstretched, anxious, living environment suddenly change etc. can aggravate disease and instead
It is multiple.Currently, clinical treatment neurodermatitis mostly uses Histamine agents object, calcium agent etc. antipruritic to the ill, it is aided in vitamin B complex
Clothes；Sedative can be selected in itch serious person；The general originator of fash can give procaine intravenous closing or tripterygium wilfordii class medicine is used in combination
Object.Although its is quick, only symptomatic treatment, there are palliative and easy to recur deficiencies.
It is some studies have shown that neurodermatitis with psychoneural because being known as apparent correlation, furthermore long-term gastrointestinal tract function
Energy obstacle, cryptorrhea and infection focus etc. are likely to become pathogenic factors.Clinically occasionally have using antidepressants and treats
The skin diseases such as obstinate pruritus, neurodermatitis, such as trimeprimine and chlorpromazine, facilitating treatment chronic dermatosis often has
Itch and sleep disordered, however these antidepressants also have many side effects, it is also possible to which it is mutual to generate drug with dermatologic
Effect, and be not that every kind of antidepressants can be used for the treating for skin disease such as neurodermatitis.
Hemp (scientific name: Cannabis sativa L.) Cannabaceae, Cannabis plant, You Mingma, Chinese fiber crops, fire fiber crops, mountain silk
Seedling, jute have important agricultural and medical value.It can be made one in hemp containing a kind of toxic component THC (tetrahydrocannabinol)
Unreal habituation is caused, drugs can be made, was once forbidden cultivating within suitable long-term.Since the economy of hemp, medical value are high, specialize in industrial
The raw material hemp on way is referred to as " industrial hemp ", and tetrahydrocannabinol (THC) content in growth period hemp floral leaf is less than thousand points
Three, do not have extract toxic component tetrahydrocannabinol value or sucked directly as drugs, can legal carry out scale
Plantation is utilized with industrialized developing.
Cannboid is the active material by extracting, synthesizing in natural plants hemp.Currently, people divide from hemp plant
More than 500 substances are separated out, wherein at least 86 kinds of Cannabinoids compound.Cannabinoids compound is peculiar in hemp plant
A substance, be main active constituent in cannabis plants, in relation to it research be always hemp research hot spot.Hemp is planted
Main Cannabinoids compound has tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), secondary hemp two in strain
Phenol (CBDV), tetrahydrocannabinol (THCV) etc., wherein former three accounts for 90% or more of Cannabinoids compound.
TV Zanelati etc. (Antidepressant-like effects of cannabidiol in mice:
possible involvement of 5-HT1A receptors,British journal of pharmacology,2010)
It was found that cannabidiol can be by activating 5-HT1AReceptor-inducible antidepression sample effect, it is believed that cannabidiol has the anti-suppression in mouse
Strongly fragrant activity.THC or cannabidiol are disclosed in patent US2014302086 and at least one selected from citric acid, ascorbic acid, mandarin orange
The small molecule compositions of tangerine essential oil etc. refer to that above-mentioned composition can treat neurodermatitis.Patent WO0206999A2 is disclosed
Containing the cannboid total weight at least drug of 80wt%, wherein the weight ratio of THC/CBD is 75:25-20:80, and is referred to above-mentioned
Composition can be used for treating neurodermatitis.However the above-mentioned prior art has only carried out the therapeutical uses of the composition simply
Enumerate, specification does not act on THC or cannabidiol in neurodermatitis and specifically being verified, and
Composition in US2014302086 can also alleviate the ingredient of neurodermatitis containing other, be difficult clear THC or hemp two
The effect of phenol can not clearly show that CBD or THC can treat the conclusion of neurodermatitis from above-mentioned in the prior art.
Present inventor takes a large amount of research, refreshing in treatment to the Cannabinoids compound of natural botanical source
It is verified through the effect in terms of property dermatitis, is screened in a variety of Cannabinoids compounds, and largely face
Bed test successfully specifies that several Cannabinoids compounds and combinations thereof have apparent curative effect to neurodermatitis finally.
Summary of the invention
After having read the detailed description of preferred embodiment and appended claims, the purpose of the present invention, advantage and use
Way will show those skilled in the art.The present invention is directed to for insufficient, hair present on the treatment of existing neurodermatitis
Existing Cannabinoids compound can treat neurodermatitis, can be used for preparing the drug for the treatment of neurodermatitis.
And the present invention provides the methods and composition preparation that use these compositions treatment neurodermatitis
Treat the application in the drug of neurodermatitis.
The present invention is intended to provide one or more Cannabinoids compounds or its pharmaceutical salt are in preparation for treating mind
Purposes in pharmaceutical composition through property dermatitis.
Preferably, the present invention provides be selected from tetrahydrocannabinol (THC), cannabidiol (CBD), cannabidivarin
(CBDV), one of tetrahydrocannabinol (THCV) Cannabinoids compound or its pharmaceutical salt are being prepared separately for controlling
Treat the purposes in the pharmaceutical composition of neurodermatitis.
Preferably, the present invention provides Cannabinoids compounds or its pharmaceutical salt to prepare for treating nerve skin
Purposes in scorching pharmaceutical composition, the Cannabinoids compound are selected from:
(1) combination of tetrahydrocannabinol (THC) and tetrahydrocannabinol (THCV)；
(2) combination of cannabidiol (CBD) and cannabidivarin (CBDV)；
(3) combination of tetrahydrocannabinol (THC) and cannabidivarin (CBDV)；
(4) combination of cannabidiol (CBD) and tetrahydrocannabinol (THCV)；
(5) combination of cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV)；
(6) combination of tetrahydrocannabinol (THC), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV).
The present invention also provides a kind of for treating the composition of neurodermatitis, including 1) Cannabinoids compound or its
Pharmaceutical salt, 2) one or more pharmaceutically acceptable carriers or excipient.
Preferably, the Cannabinoids compound is selected from tetrahydrocannabinol (THC), cannabidiol (CBD), secondary hemp two
One of phenol (CBDV), tetrahydrocannabinol (THCV).
Preferably, the Cannabinoids compound is selected from:
(1) combination of tetrahydrocannabinol (THC) and tetrahydrocannabinol (THCV)；
(2) combination of cannabidiol (CBD) and cannabidivarin (CBDV)；
(3) combination of tetrahydrocannabinol (THC) and cannabidivarin (CBDV)；
(4) combination of cannabidiol (CBD) and tetrahydrocannabinol (THCV)；
(5) combination of cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV)；
(6) combination of tetrahydrocannabinol (THC), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV).
It is furthermore preferred that the Cannabinoids compound is selected from:
(1) combination of tetrahydrocannabinol (THC) and tetrahydrocannabinol (THCV) by weight tetrahydrocannabinol (THC) and
Tetrahydrocannabinol (THCV) is 100:5-20；
(2) combination of cannabidiol (CBD) and cannabidivarin (CBDV) is by weight cannabidiol (CBD) and time hemp
Diphenol (CBDV) is 100:20-50；
(3) combination of tetrahydrocannabinol (THC) and cannabidivarin (CBDV) by weight tetrahydrocannabinol (THC) and time
Cannabidiol (CBDV) is 100:40-100；
(4) combination of cannabidiol (CBD) and tetrahydrocannabinol (THCV) is by weight cannabidiol (CBD) and tetrahydro
Secondary cannabinol (THCV) is 100:2.5-10；
(5) combination of cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) is by weight big
Numb diphenol (CBD), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) are 100:20-50:2.5-10；
(6) combination of tetrahydrocannabinol (THC), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) is by weight
Tetrahydrocannabinol (THC), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) are 100:40-100:5-20.
Pharmaceutical salt of the present invention includes the acid-addition salts formed with inorganic acid or organic acid, the inorganic acid example
Such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid；The organic acids for example acetic acid, propionic acid, caproic acid, enanthic acid, pyruvic acid, lactic acid,
Malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o- (4- hydroxy benzoyl) benzene
Formic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, trimethylacetic acid, butylacetic acid, dodecyl sulphate, gluconic acid, paddy ammonia
Acid, naphthoic acid, salicylic acid, stearic acid etc..
Composition of the present invention can be made into specific dosage form, for example oral by any approach appropriate, rectum,
Nose, lung, part (including oral cavity and sublingual), in transdermal, brain pond, intraperitoneal, vagina and parenteral (including subcutaneous, intramuscular, sheath
It is interior, intravenous and intradermal) approach administration, preferably oral route.It should be understood that optimization approach depends on the general of patient to be treated
Situation and age, the property of disease to be treated and concrete activity ingredient or selected active constituent.
The composition of oral administration includes solid dosage forms, such as capsule, tablet, sugar coated tablet, pill, pastille, powder agent
And granule.
The composition of oral administration further includes liquid dosage form, such as solution, emulsion, suspension, syrup and elixir.
The composition of parenteral includes sterile aqueous and non-aqueous injection solutions, dispersion liquid, suspension or lotion, with
And the aseptic powdery of sterile injectable solution or dispersion liquid is redissolved in front of use.
The suitable form of administration of others includes suppository, spray, cream, gelling agent, inhalant, patch, implants etc..
Composition of the invention or composition produced by the invention can be given by any approach appropriate, such as with
The forms such as tablet, capsule, powder agent, syrup are oral, or parental injection as a solution.In order to prepare this combination
Methods known in the art can be used in object, and in the art usually used any pharmaceutically acceptable carrier, dilute can be used
Release agent, excipient or other additives.
For parenteral, can be used the aseptic aqueous solutions of one or more active constituents, aqueous propylene glycol solution,
Aqueous vitamin e solution or sesame oil or peanut oil solution.If it is necessary, this aqueous solution should be buffered appropriately, and liquid
Body diluent is made of enough salt or glucose isotonic first.Aqueous solution be particularly suitable for it is intravenous, intramuscular, subcutaneous and
Intraperitoneal administration.Sterile aqueous media used by being made is easy by standard technique well known by persons skilled in the art.
It is (preferably sterile by the way that one or more active constituents and possible additive are dissolved in a part of solvent for injection
Water), solution is adjusted to required volume, and sterile solution is simultaneously filled into ampoule or bottle appropriate, and it is molten can to prepare injection
Liquid.Common any appropriate additive, such as tonicity agents, preservative, antioxidant in the art etc. can be added.
Appropriate pharmaceutical carrier includes inert solid diluent or filler, aseptic aqueous solution and various organic solvents.
The example of solid carrier has lactose, carclazyte, sucrose, cyclodextrin, talcum powder, agar, pectin, Arabic gum, tristearin
Acid, the lower alkyl ether of cellulose, cornstarch, potato starch, talcum powder, magnesium stearate, gelatin etc..
The auxiliary material or additive of any other the purpose of being commonly used in coloring, flavoring, anti-corrosion can be used, as long as them and work
Property ingredient or used ingredient are compatible.
The example of liquid-carrier has syrup, peanut oil, olive oil, phosphatide, fatty acid, fatty acid amine, polyoxyethylene and water.
Similar, carrier or diluent may include any slow-release material known in the art, such as mix individually or with wax
Glycerin monostearate or distearin.
The composition formed and mixing one or more active constituents of the invention with pharmaceutically acceptable carrier,
It then can be to be suitble to the various dosage forms of open administration route easily to give.It can be facilitated by method known in pharmaceutical field
Ground has preparation with unit dosage forms.
Active constituent of the invention can be formulated as similar or dissimilar pharmaceutical composition and its unit dosage forms.
It preferably, is 2.5-400mg Cannabinoids compound containing unit dose in pharmaceutical composition of the present invention
Or its pharmaceutical salt, it is furthermore preferred that containing unit dose in the pharmaceutical composition is 25-300mg Cannabinoids chemical combination
Object or its pharmaceutical salt, most preferably, in the pharmaceutical composition containing unit dose is 50-200mg Cannabinoids
Close object or its pharmaceutical salt, in embodiments of the present invention, in the pharmaceutical composition containing unit dose be 25mg,
30mg、40mg、50mg、60mg、70mg、80mg、90mg、100mg、110mg、120mg、130mg、140mg、150mg、160mg、
170mg, 180mg, 190mg or 200mg Cannabinoids compound or its pharmaceutical salt.
The present invention also provides a kind of prevention and/or the method for the treatment of neurodermatitis, the method includes applying daily
It is 1-500mg Cannabinoids compound or its pharmaceutical salt with drug dose, it is furthermore preferred that daily administration drug dose is
25-300mg Cannabinoids compound or its pharmaceutical salt, most preferably, daily administration drug dose are 50-200mg hemp
Chlorins compound or its pharmaceutical salt, in embodiments of the present invention, daily administration drug dose can also for 25mg,
30mg、40mg、50mg、60mg、70mg、80mg、90mg、100mg、110mg、120mg、130mg、140mg、150mg、160mg、
170mg, 180mg, 190mg or 200mg Cannabinoids compound or its pharmaceutical salt.
Cannabinoids compound of the present invention or its pharmaceutical salt can be chemosynthesis product, biosynthesis produces
Object, plant extracts are prepared using other modes.Preferably, Cannabinoids compound of the present invention is that plant mentions
Object is taken, the plant can be the shell of the stalk core of hemp Cannabis sativa L., flower, leaf, root and/or seed.
When Cannabinoids compound of the present invention is plant extracts, Extraction solvent can be low mass molecule alcohol (such as first
Alcohol, ethyl alcohol, butanol or propyl alcohol)；Acetic acid esters (such as methyl acetate or ethyl acetate)；Ketone (such as acetone)；Ether (such as methyl ether or
Ether)；Low-boiling aliphatic hydrocarbon or aromatic hydrocarbon or chlorinated hydrocabon.The method of extraction includes:
(1) using or mixtures thereof said extracted solvent of about 3-10 times weight to hemp Cannabis sativa L.'s
Stalk core, flower, leaf, root and/or seed shell be heated to reflux, preferably at least handle about 1 hour, be then filtered to remove residue, with
After remove solvent, preferably vacuum condition remove solvent, by the medicinal extract of acquisition about 110-135 DEG C of temperature heat about 40 minutes,
Chromatographic isolation is then carried out, is preferred for chromatographic flowing phase mixture by methanol/water and acetic acid or ethanol/water and acetic acid
Composition.
(2) using or mixtures thereof said extracted solvent of about 3-10 times weight to the stalk core of hemp, flower, leaf, root and/or
The shell of seed is heated to reflux, and is preferably at least handled about 1 hour, then filtering is at least extracted with the sodium hydrate aqueous solution of 1-10%
Take twice, the sodium hydrate aqueous solution preferably comprises from about the ethyl alcohol of 20wt%, extract liquor is mixed with 5% sulfuric acid solution with
Make pH value about 2-4, then uses low boiling point solvent (such as low boiling point aliphatic hydrocarbon, aromatic hydrocarbon, chlorohydrocarbon, methyl acetate, acetic acid second
Ester or its mixture) it extracts at least twice, solvent is removed under cryogenic vacuum, is then carried out chromatographic isolation, is preferred for chromatography
The flowing phase mixture of method is made of methanol/water and acetic acid or ethanol/water and acetic acid.
Patient of the present invention is mammal, such as people, mouse, rat, cavy, dog, cat, horse, ox, pig or non-
People primate, such as monkey, chimpanzee or baboon.Preferably, the patient behaves.
Unless otherwise stated, term " pharmaceutically acceptable carrier or excipient " is meant that the ingredient without biology
Activity or other bad active impurity, such as the ingredient can be included in disclosed pharmaceutical preparation and give patient, but not cause
Significant bad biological effect generates interaction with the other compositions for including in said preparation in harmful manner.
Unless otherwise stated, term " treatment " includes inhibition, delay, mitigation, decrease, limitation, mitigation or recession disease
Disease, obstacle, illness or state, generation and/or process and/or its symptom.
Unless otherwise stated, term "comprising" indicates " opening " or " inclusive " term, so that they include enumerating
Element, but also allow to include additional, unmentioned element.
Unless otherwise stated, term " about " generally means that +/- the 5% of described value, more generally refer to the +/- of described value
4%, more generally refer to +/- the 3% of described value, more generally refer to +/- the 2% of described value, more generally refers to +/- the 1% of described value, it is more logical
Often refer to +/- the 0.5% of described value.
The present invention demonstrates Cannabinoids compound or its pharmaceutical salt to treatment nerve skin by largely research
Inflammation has positive effect, and individual Cannabinoids compound and said combination all have the various diseases for improving neurodermatitis
Shape can be used to prepare the drug for the treatment of neurodermatitis.
Specific embodiment
It should be noted that in the absence of conflict, the features in the embodiments and the embodiments of the present application can phase
Mutually combination.Below in conjunction with embodiment, the present invention will be described in detail.
1 capsule unit dosage form of embodiment
Formulation ingredients: cannabidiol 200mg
Microcrystalline cellulose 90mg
Pregelatinized starch 100mg
Cross-linked carboxymethyl cellulose 7mg
Magnesium stearate 0.5mg
Preparation method: the active constituent is sieved, and is mixed with auxiliary material, is filled this blend into hard gelatin capsule.
2 capsule unit dosage form of embodiment
Formulation ingredients: cannabidiol 400mg
Microcrystalline cellulose 100mg
Pregelatinized starch 150mg
Cross-linked carboxymethyl cellulose 10mg
Magnesium stearate 0.2mg
The preparation method is the same as that of Example 1.
3 tablet unit dosage form of embodiment
Formulation ingredients: tetrahydrocannabinol 100mg
Dextrin 100mg
Microcrystalline cellulose 25mg
Polyvinylpyrrolidone 10mg
Sodium carboxymethyl starch 15mg
Magnesium stearate 1mg
Preparation method: the active constituent is sieved, and with dextrin, microcrystalline cellulose, polyvinylpyrrolidone, carboxymethyl
Sodium starch mixing is until form uniform mixture, sieving obtains mixture, and mixes with magnesium stearate.Then by resulting powder
Type mixture is pressed into the tablet for needing shapes and sizes.
4 tablet unit dosage form of embodiment
Formulation ingredients: tetrahydrocannabinol 40mg
Pregelatinized starch 150mg
Microcrystalline cellulose 25mg
Sodium carboxymethyl starch 15mg
Magnesium stearate 1mg
Preparation method: the active constituent is sieved, and mixed with pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch
It closes until forming uniform mixture, sieving obtains mixture, and mixes with magnesium stearate.Then by resulting powdered mixture
It is pressed into the tablet for needing shapes and sizes.
5 tablet unit dosage form of embodiment
Formulation ingredients: cannabidiol 200mg
Cannabidivarin 40mg
Dextrin 150mg
Sodium carboxymethyl starch 15mg
Magnesium stearate 1mg
Preparation method: the active constituent is sieved, and is mixed with dextrin, sodium carboxymethyl starch until being formed uniform mixed
Object is closed, sieving obtains mixture, and mixes with magnesium stearate.Then resulting powdered mixture is pressed into and needs shape and big
Small tablet.
6 tablet unit dosage form of embodiment
Formulation ingredients: tetrahydrocannabinol 100mg
Cannabidivarin 40mg
Pregelatinized starch 150mg
Microcrystalline cellulose 25mg
Sodium carboxymethyl starch 15mg
Magnesium stearate 1mg
Preparation method: the active constituent is sieved, and mixed with pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch
It closes until forming uniform mixture, sieving obtains mixture, and mixes with magnesium stearate.Then by resulting powdered mixture
It is pressed into the tablet for needing shapes and sizes.
7 tablet unit dosage form of embodiment
Formulation ingredients: cannabidiol 200mg
Tetrahydrocannabinol 10mg
Pregelatinized starch 150mg
Microcrystalline cellulose 25mg
Polyvinylpyrrolidone 10mg
Sodium carboxymethyl starch 15mg
Magnesium stearate 1mg
Preparation method: the active constituent is sieved, and with pregelatinized starch, microcrystalline cellulose, polyvinylpyrrolidone,
Sodium carboxymethyl starch mixing is until form uniform mixture, sieving obtains mixture, and mixes with magnesium stearate.Then by institute
The powdered mixture obtained is pressed into the tablet for needing shapes and sizes.
8 tablet unit dosage form of embodiment
Formulation ingredients: tetrahydrocannabinol 100mg
Tetrahydrocannabinol 10mg
Pregelatinized starch 150mg
Microcrystalline cellulose 25mg
Polyvinylpyrrolidone 10mg
Sodium carboxymethyl starch 15mg
Magnesium stearate 1mg
Preparation method: the active constituent is sieved, and with pregelatinized starch, microcrystalline cellulose, polyvinylpyrrolidone,
Sodium carboxymethyl starch mixing is until form uniform mixture, sieving obtains mixture, and mixes with magnesium stearate.Then by institute
The powdered mixture obtained is pressed into the tablet for needing shapes and sizes.
9 tablet unit dosage form of embodiment
Formulation ingredients: tetrahydrocannabinol 100mg
Cannabidivarin 40mg
Tetrahydrocannabinol 10mg
Dextrin 150mg
Sodium carboxymethyl starch 15mg
Magnesium stearate 1mg
Preparation method: the active constituent is sieved, and is mixed with dextrin and sodium carboxymethyl starch until being formed uniform
Mixture, sieving obtains mixture, and mixes with magnesium stearate.Then resulting powdered mixture is pressed into need shape and
The tablet of size.
10 tablet unit dosage form of embodiment
Formulation ingredients: cannabidiol 200mg
Cannabidivarin 40mg
Tetrahydrocannabinol 10mg
Dextrin 150mg
Sodium carboxymethyl starch 15mg
Magnesium stearate 1mg
Preparation method: the active constituent is sieved, and is mixed with dextrin and sodium carboxymethyl starch until being formed uniform
Mixture, sieving obtains mixture, and mixes with magnesium stearate.Then resulting powdered mixture is pressed into need shape and
The tablet of size.
11 injection unit dosage forms of embodiment (10mL liquid drugs injection)
Formulation ingredients: tetrahydrocannabinol 500mg
Appropriate hydroxypropyl-β-cyclodextrin
0.1mol/L HCl is appropriate
Appropriate sodium chloride
Water for injection adds to 1000mL
Preparation method: water for injection about 800ml is taken, appropriate hydroxypropyl-β-cyclodextrin is added, adds tetrahydrocannabinol
Ingredient is allowed to dissolve, and adjusting pH value with 0.1mol/L HCl is 6.2-6.5, adds to the full amount of water for injection, stirs evenly, and sodium chloride is added
To isotonic, it is filling to be passed through steam 121 DEG C of sterilizings 15min, 10ml in ampoule for filtration, encapsulating for allotment.
12 injection unit dosage forms of embodiment (10mL powder-injection)
Formulation ingredients: cannabidivarin 4000mg
Mannitol 50g
0.1mol/L HCl is appropriate
Appropriate hydroxypropyl-β-cyclodextrin
Appropriate sodium chloride
Water for injection adds to 1000mL
Preparation method: taking water for injection about 800ml, be added recipe quantity mannitol and appropriate hydroxypropyl-β-cyclodextrin, then
Each cannboid active constituent is added to be allowed to dissolve, stirring is lower to add appropriate 0.1mol/L HCl to adjust pH value for 6.2-6.5, so
After add to the full amount of water for injection, sodium chloride is added and deploys to isotonic, filtration is freeze-dried according to freeze drying powder injection technique,
Powder-injection is made, 10ml is filling.
Embodiment 13 is administered alone Cannabinoids compound and causes the influence of effect of itching to histamine phosphate
Experimental principle:
Feel itch by central regulation, the adjusting is by being located at the excitement of neuron in spinal cord and inhibiting circuit and opium sample system
What system was realized, therefore psychological factor can cause nerve immunity to change, and make central nervous excitation and inhibit functional disturbance, lead to feel of itching
Adjustment mechanism, which gets muddled, causes maincenter to be itched feel.Cannabinoids compound can then pass through cannabinoid CB 1 and/or CB2 receptor tune
Nervous centralis is saved, improvement itch is reached.
Implementation method:
Take cavy 70, be divided at random blank control group (distilled water 100mg/ days), cannabidiol group (50mg/ days,
100mg/ days, 200mg/ days), tetrahydrocannabinol group (40mg/ days, 80mg/ days, 100mg/ days), cannabidivarin group (40mg/
It, 80mg/ days, 100mg/ days), tetrahydrocannabinol group (5mg/ days, 10mg/ days, 20mg/ days), control group (chlorpheniramine
10mg/ days), every group 5.Dorsal portion shaving 2cm × 2cm after each group cavy is right is administered orally according to above-mentioned dosage respectively,
Successive administration 3 days.It is administered the 3rd day, is abraded at shaving respectively with coarse sandpaper, to injure epidermis, have slight oozing of blood for degree, 10 minutes
Afterwards, 0.01% histamine phosphate solution of 0.05ml is dripped at every cavy surface of a wound respectively, hereafter every 3min phosphoric acid group incremented by successively
Concentration (such as 0.02%/0.03%/0.04%/0.05%/0.06% etc.) the histamine phosphate solution of amine is until cavy returns
When head licks sufficient, the total amount of the given histamine of every cavy is recorded, using this total amount as itch-threshold.
Experimental result:
From this experiment as can be seen that cannabidiol and tetrahydrocannabinol, which is administered alone, can be relieved histamine phosphate and cause
Itch effect.
Embodiment 14 applies Cannabinoids compound composition and causes the influence of effect of itching to histamine phosphate
Although be administered alone cannabidiol and tetrahydrocannabinol show it is certain histamine phosphate is caused to itch the alleviation of effect,
But it prefers to it can be found that having the active constituent of more preferably effect.Therefore, this experiment compares different group Cannabinoids chemical combination
Compositions cause the influence of effect of itching to histamine phosphate.
Implementation method:
Cavy 90 are taken, it is random to divide equally are as follows:
Tetrahydrocannabinol (THC) and tetrahydrocannabinol (THCV) drug combination group；
Cannabidiol (CBD) and cannabidivarin (CBDV) drug combination group；
Tetrahydrocannabinol (THC) and cannabidivarin (CBDV) drug combination group；
Cannabidiol (CBD) and tetrahydrocannabinol (THCV) drug combination group；
Cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) drug combination group；
Tetrahydrocannabinol (THC), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) drug combination group:
Every group 5, experimental procedure is the same as embodiment 13.
Experimental result:
From this experiment as can be seen that compared with cannabidiol and tetrahydrocannabinol is administered alone, two or more cannboids
The combination of class compound has more preferably effect, this may be from the receptor binding site difference phase of different Cannabinoids compound effects
It closes.
The clinical research of 15 Cannabinoids compounds on nerve dermatitis of embodiment
Select the generalized neurodermatitis patient of Dermatology Outpatient Department and inpatient department.
Diagnostic criteria: meet the diagnosis in " clinical dermatology " in relation to neurodermatitis.Its clinical manifestation mainly with
Skin lichenification and violent itch are characterized.It mostly occurs in nape or its two sides, the fossa cubitalis, rouge nest, forearm, thigh, shank
And lumbosacral region etc..Subjective symptoms is often the violent itch of paroxysmal, night be very, most of patients have dizziness, insomnia, irritable,
The neurasthenic symptom such as anxious.
Exclusion criteria: 1. skin lesion merges bacterium or fungal infections；2. gestation or breast feeding women；3. in first 1 week selected
The used glucocorticoid medicine in part, or took Loratadine person；4. system applied glucocorticoids in 1 month
Drug person；5. known to research medicine and its matrix components allergy sufferers；6. having Chronic Liver, kidney diaseases or other severe illness person；⑦
There are diabetes or serious immunologic hypofunction person.
90 clinical observations of neurodermatitis patient made a definite diagnosis are selected, patient is randomly divided into nine groups, wherein Cannabinoids
Eight groups of He Wu treatment group, totally 80 people, women 24, the age 30~61 years old, uses embodiment 1/3/5/6/7/8/9/ by male 56
The preparation of 10 preparations, every group of 10 men and women random selection.10 people of control group doxepin hydrochloride group, wherein male 5, women 5,
Age 30~61 years old.
Treatment method: preparation prepared by the oral embodiment 1/3/5/6/7/8/9/10 of Cannabinoids compound treatment group, 1
Secondary/d takes before sleeping, and even served 2 weeks；Control group uses doxepin hydrochloride 25mg/ times, takes orally, 1 time/d, takes before sleeping, even served 2
Week.
Observation index includes itch degree, degree of inflammation, scales of skin that peel off plumpness degree and target skin lesion face, selects the skin lesion of most serious
Position is as target cutaneous lesion, and area, clinical symptoms and the sign of record target skin lesion change when each follow-up, does not have to during treatment
Other any drugs.Carry out observation, the assessment of skin lesion part in treating first 1 week, treating in 2 weeks and drug withdrawal 1 month weekly.Skin lesion
Methods of marking is as follows:
Curative effect determinate standard: standards of grading are that each index scores by 4 grades of point systems in each assessment, i.e., 0 is
Nothing, 1 be it is slight, 2 be moderate, and 3 be severe.The rotten to the corn scoring < 1 of all patients is required to divide when entering group, skin lesion area is then remembered without exception
It is 3 points, and records the aggregate value of each index scoring.Efficacy determination: sentenced using the percentage of integrated value reduction as therapeutic index
Disconnected curative effect, the calculation formula of therapeutic index are as follows: integrated when (integral when integrating total-each follow-up when first visit is total)/first visit
Total × 100%.Therapeutic index > 90%, for recovery from illness, 61%~89%, to be effective, 20%~60% is effective, < 20%,
It is invalid.
Clinical test results are as follows:
From this experiment as can be seen that cannabidiol, tetrahydrocannabinol is administered alone and two or more hemps are administered in combination
The combination of chlorins compound all has clinical efficacy to neurodermatitis, and the group of two or more Cannabinoids compounds is administered simultaneously
Closing has more preferably effect.
Claims (8)
1. in tetrahydrocannabinol (THC), cannabidiol (CBD), cannabidivarin (CBDV), tetrahydrocannabinol (THCV)
A kind of Cannabinoids compound or its pharmaceutical salt be prepared separately in the pharmaceutical composition for treating neurodermatitis
Purposes.
2. Cannabinoids compound or its pharmaceutical salt are preparing the use in the pharmaceutical composition for treating neurodermatitis
On the way, the Cannabinoids compound is selected from:
(1) combination of tetrahydrocannabinol (THC) and tetrahydrocannabinol (THCV)；
(2) combination of cannabidiol (CBD) and cannabidivarin (CBDV)；
(3) combination of tetrahydrocannabinol (THC) and cannabidivarin (CBDV)；
(4) combination of cannabidiol (CBD) and tetrahydrocannabinol (THCV)；
(5) combination of cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV)；
(6) combination of tetrahydrocannabinol (THC), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV).
3. Cannabinoids compound as claimed in claim 2 or its pharmaceutical salt are preparing the medicine for treating neurodermatitis
Purposes in compositions, in which:
(1) by weight tetrahydrocannabinol (THC) and four in the combination of tetrahydrocannabinol (THC) and tetrahydrocannabinol (THCV)
Hydrogen time cannabinol (THCV) is 100:5-20；
(2) combination of cannabidiol (CBD) and cannabidivarin (CBDV) is by weight cannabidiol (CBD) and cannabidivarin
It (CBDV) is 100:20-50；
(3) combination of tetrahydrocannabinol (THC) and cannabidivarin (CBDV) is by weight tetrahydrocannabinol (THC) and time hemp
Diphenol (CBDV) is 100:40-100；
(4) combination of cannabidiol (CBD) and tetrahydrocannabinol (THCV) is big by weight cannabidiol (CBD) and tetrahydro time
Numb phenol (THCV) is 100:2.5-10；
(5) combination of cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) is by weight hemp two
Phenol (CBD), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) are 100:20-50:2.5-10；
(6) combination of tetrahydrocannabinol (THC), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) is by weight tetrahydro
Cannabinol (THC), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) are 100:40-100:5-20.
4. a kind of pharmaceutical composition for treating neurodermatitis, which is characterized in that described pharmaceutical composition is composed of the following components:
1) Cannabinoids compound or its pharmaceutical salt；
2) one or more pharmaceutically acceptable carriers or excipient；
The Cannabinoids compound is selected from tetrahydrocannabinol (THC), cannabidiol (CBD), cannabidivarin (CBDV), four
One of hydrogen time cannabinol (THCV).
5. a kind of pharmaceutical composition for treating neurodermatitis, which is characterized in that described pharmaceutical composition is composed of the following components:
1) Cannabinoids compound or its pharmaceutical salt；
2) one or more pharmaceutically acceptable carriers or excipient；
The Cannabinoids compound is selected from:
(1) combination of tetrahydrocannabinol (THC) and tetrahydrocannabinol (THCV)；
(2) combination of cannabidiol (CBD) and cannabidivarin (CBDV)；
(3) combination of tetrahydrocannabinol (THC) and cannabidivarin (CBDV)；
(4) combination of cannabidiol (CBD) and tetrahydrocannabinol (THCV)；
(5) combination of cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV)；
(6) combination of tetrahydrocannabinol (THC), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV).
6. pharmaceutical composition as claimed in claim 5, which is characterized in that the Cannabinoids compound is selected from:
(1) combination of tetrahydrocannabinol (THC) and tetrahydrocannabinol (THCV) is by weight tetrahydrocannabinol (THC) and tetrahydro
Secondary cannabinol (THCV) is 100:5-20；
(2) combination of cannabidiol (CBD) and cannabidivarin (CBDV) is by weight cannabidiol (CBD) and cannabidivarin
It (CBDV) is 100:20-50；
(3) combination of tetrahydrocannabinol (THC) and cannabidivarin (CBDV) is by weight tetrahydrocannabinol (THC) and time hemp
Diphenol (CBDV) is 100:40-100；
(4) combination of cannabidiol (CBD) and tetrahydrocannabinol (THCV) is big by weight cannabidiol (CBD) and tetrahydro time
Numb phenol (THCV) is 100:2.5-10；
(5) combination of cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) is by weight hemp two
Phenol (CBD), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) are 100:20-50:2.5-10；
(6) combination of tetrahydrocannabinol (THC), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) is by weight tetrahydro
Cannabinol (THC), cannabidivarin (CBDV) and tetrahydrocannabinol (THCV) are 100:40-100:5-20.
7. according to composition described in claim 4-6 any one, which is characterized in that described pharmaceutical composition is selected from capsule
Agent, tablet, pill, pastille, granule, solution, emulsion, suspension, syrup, aseptic injection, aseptic powdery, suppository,
Spray, ointment, cream, gelling agent, inhalant, dermal patch or implants.
8. the method for preparing any one of claim 4-6 composition, which comprises the steps of: will be one or more
The Cannabinoids compound or its pharmaceutical salt, mix in proportion, obtain the composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710538732.XA CN109200046A (en) | 2017-07-04 | 2017-07-04 | Application of the Cannabinoids compound in treatment neurodermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710538732.XA CN109200046A (en) | 2017-07-04 | 2017-07-04 | Application of the Cannabinoids compound in treatment neurodermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109200046A true CN109200046A (en) | 2019-01-15 |
Family
ID=64993688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710538732.XA Pending CN109200046A (en) | 2017-07-04 | 2017-07-04 | Application of the Cannabinoids compound in treatment neurodermatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109200046A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020097765A1 (en) * | 2018-11-12 | 2020-05-22 | 汉义生物科技（北京）有限公司 | Use of cannabinoid compound in neurodermatitis treatment |
| CN111557900A (en) * | 2020-05-22 | 2020-08-21 | 广州大洲生物医药科技有限公司 | Cannabidiol cream, preparation method and application thereof |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| WO2021135665A1 (en) * | 2019-12-31 | 2021-07-08 | 汉义生物科技（北京）有限公司 | Application of tetrahydrocannabivarin in prevention and/or treatment of pulmonary arterial hypertension |
| CN113116867A (en) * | 2019-12-31 | 2021-07-16 | 汉义生物科技（北京）有限公司 | Composition for preventing and/or treating influenza |
| CN113116869A (en) * | 2019-12-31 | 2021-07-16 | 汉义生物科技（北京）有限公司 | Composition for preventing and/or treating depression |
| US11084770B2 (en) | 2016-12-07 | 2021-08-10 | Treehouse Biotech, Inc. | Cannabis extracts |
| US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
| CN115052868A (en) * | 2020-02-06 | 2022-09-13 | 伦敦制药与研究公司 | Cannabinoid sulfate, and salts and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1547479A (en) * | 2001-03-06 | 2004-11-17 | ��֢�о���˹��˹��Э�� | Pharmaceutical composition prepared from cannabis extract |
| US20120295968A1 (en) * | 2011-05-20 | 2012-11-22 | Brooks Kelly Research, Llc | Pharmaceutical Composition Comprising Cannabinoids |
| WO2017055846A1 (en) * | 2015-09-29 | 2017-04-06 | Gw Pharma Limited | Use of cannabinoids in the treatment of inflammatory skin diseases |
-
2017
- 2017-07-04 CN CN201710538732.XA patent/CN109200046A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1547479A (en) * | 2001-03-06 | 2004-11-17 | ��֢�о���˹��˹��Э�� | Pharmaceutical composition prepared from cannabis extract |
| US20120295968A1 (en) * | 2011-05-20 | 2012-11-22 | Brooks Kelly Research, Llc | Pharmaceutical Composition Comprising Cannabinoids |
| WO2017055846A1 (en) * | 2015-09-29 | 2017-04-06 | Gw Pharma Limited | Use of cannabinoids in the treatment of inflammatory skin diseases |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11084770B2 (en) | 2016-12-07 | 2021-08-10 | Treehouse Biotech, Inc. | Cannabis extracts |
| US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| WO2020097765A1 (en) * | 2018-11-12 | 2020-05-22 | 汉义生物科技（北京）有限公司 | Use of cannabinoid compound in neurodermatitis treatment |
| WO2021135665A1 (en) * | 2019-12-31 | 2021-07-08 | 汉义生物科技（北京）有限公司 | Application of tetrahydrocannabivarin in prevention and/or treatment of pulmonary arterial hypertension |
| CN113116867A (en) * | 2019-12-31 | 2021-07-16 | 汉义生物科技（北京）有限公司 | Composition for preventing and/or treating influenza |
| CN113116869A (en) * | 2019-12-31 | 2021-07-16 | 汉义生物科技（北京）有限公司 | Composition for preventing and/or treating depression |
| CN113116868A (en) * | 2019-12-31 | 2021-07-16 | 汉义生物科技（北京）有限公司 | Use of tetrahydrocannabivarin for the prevention and/or treatment of pulmonary hypertension |
| CN113116867B (en) * | 2019-12-31 | 2022-08-23 | 汉义生物科技（北京）有限公司 | Composition for preventing and/or treating influenza |
| CN115052868A (en) * | 2020-02-06 | 2022-09-13 | 伦敦制药与研究公司 | Cannabinoid sulfate, and salts and uses thereof |
| CN111557900A (en) * | 2020-05-22 | 2020-08-21 | 广州大洲生物医药科技有限公司 | Cannabidiol cream, preparation method and application thereof |
| CN111557900B (en) * | 2020-05-22 | 2023-05-12 | 广州大洲生物医药科技有限公司 | Cannabidiol cream, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109200046A (en) | Application of the Cannabinoids compound in treatment neurodermatitis | |
| Mazumder et al. | Phyto-pharmacology of Berberis aristata DC: a review | |
| CN101543546B (en) | Antioxidative substance and composition and use thereof | |
| US20100303935A1 (en) | Medicinal Composition | |
| Zaurov et al. | The medicinal plants of Uzbekistan and Kyrgyzstan | |
| CN101708241B (en) | Medicinal composition for eliminating dampness and relieving itching | |
| Dirar et al. | Genus Blepharis (Acanthaceae): A review of ethnomedicinally used species, and their phytochemistry and pharmacological activities | |
| Dharani et al. | An Illustrated Guide to Medicinal Plants of East Africa | |
| Boon et al. | The complete natural medicine guide to the 50 most common medicinal herbs | |
| CN102716184A (en) | Chinese medicinal composition and application thereof | |
| CN112386589B (en) | Composition for anti-anxiety/anti-depression agent and application thereof | |
| EP2260855A1 (en) | Composition containing aqueous extract of ashwaganda leaves as the active ingredient and method of producing the same | |
| EP2934561B1 (en) | Composition comprising raphanus, theobroma and passiflora for treating opioid and alcohol abuse | |
| Raj et al. | Kalanchoe pinnatum in treatment of gallstones: An ethnopharmacological review | |
| EP3225245B1 (en) | Bioactive extract obtained from vicia faba and its use in the treatment and/or prevention of neurodegenerative diseases | |
| JP2001278796A (en) | Anti-itching and antiallergic composition | |
| CN1853708B (en) | Use of Galangal fruit and its extract in pharmacy | |
| CN103006681A (en) | Compound emulsifiable paste for treating acne and preparation method thereof | |
| Prajapati et al. | Opuntia elatior Mill.(Nagaphani): A review on its ethnobotany, phytochemical and pharmacological properties | |
| Usman | Poisonous Herbal Plants: NA | |
| CA3118535C (en) | Use of cannabinoid compound in neurodermatitis treatment | |
| KR101828102B1 (en) | Composition for treating vomiting or diarrhea comprising Machili Thunbergi Cortex extract | |
| SOKOLIK et al. | RESEARCH RESULTS IN PHARMACOLOGY | |
| Boddupalli | A review on most important poisonous plants and their medicinal properties | |
| CN104042682A (en) | Traditional Chinese medicine composition for treating diabetic complication pneumonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190115 |